Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 driver mutations. The company is also developing BDTX-1535, a brain-penetrant inhibitor of EGFR mutations, including canonical, intrinsic resistance, and acquired resistance mutations; and BDTX-4933, a brain-penetrant inhibitor of oncogenic BRAF class I, II and III alterations. It has a strategic partnership with OpenEye Scientific Software, Inc. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Black Diamond Therapeutics, Inc.

Black Diamond Therapeutics is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations, expanding the addressable patient population by offering one solution for many mutations. Our mission: defeat cancer resistance and provide people living with cancer the opportunity to experience longer, healthier and more active lives. We are advancing two potent, brain-penetrant clinical-stage programs: BDTX-1535, a fourth-generation EGFR inhibitor targeting non-small cell lung cancer (NSCLC) and glioblastoma (GBM) and BDTX-4933, a RAF inhibitor targeting KRAS, NRAS and BRAF alterations in NSCLC and other solid tumors.

Biotechnology Value Fund

BVF Partners

City Hill Ventures

Wellington Management

Logos Capital

New Enterprise Associates

Invus

Nextech Invest

Roche Venture Fund

Versant Ventures

Perceptive Advisors

Black Diamond Therapeutics

Endpoints' recent coverage of a new survey on the state of the continuously evolving #NSCLC therapeutic landscape reflects progress for the field but still huge unmet need https://lnkd.in/e7AGnJqn. Fewer than one in five oncologists rated the current treatment options as excellent, and the majority are seeking additional treatment options for advanced forms of #cancer, as well as tools to assess biomarkers and other predictive methods that inform treatment efficacy. To learn more about BDTX's unique approach to expand the scope of NSCLC therapies and about its investigational MasterKey drug candidates, visit https://lnkd.in/eWvbfvKc

We expect an exciting year ahead as we continue advancing our clinical programs with the goal of enabling patients to live healthier, longer lives. We anticipate several important BDTX-1535 milestones in 2024, including Phase 2 results for the treatment of #NSCLC, as well as medical meeting presentations of Phase 1 data sets for the treatment of #GBM. We also expect BDTX-4933 Phase 1 results for the treatment of KRASm NSCLC.

Read more: https://lnkd.in/eMiiNsSg

#LungCancer #Glioblastoma

Today we announced topline results from our Phase 1 dose escalation trial in recurrent #GBM, where historical PFS ranges from 2-4 months. BDTX-1535 demonstrated promising clinical activity and more than 1/3 of patients remained on therapy greater than 4 months. These results in heavily pretreated patients are an important first step in understanding the potential of BDTX-1535 to benefit newly-diagnosed GBM patients. We anticipate results from a "window of opportunity" clinical trial of BDTX-1535 in second-line patients with high-grade glioma in 2Q 2024.

Read more: https://lnkd.in/eU7hFh8F

This weekend, Black Diamond will be in the Windy City, joining other pioneers in #oncology at the #IASLC North America Conference on Lung Cancer for robust knowledge exchange and immersion in the latest research as we further advance our pipeline of MasterKey inhibitors for #EGFR, #KRAS and #BRAF driven #NSCLC. 

To learn more about our pipeline, visit: https://lnkd.in/ek2kyjwV

#NACLC23

Lung cancer is the second most common form of cancer in both men and women in the US, according to the American Cancer Society, and November is #LungCancerAwareness Month. The more than 200,000 diagnoses each year inspire, encourage, and empower us every day to relentlessly pursue our mission of developing potentially life changing treatments for patients living with mutated forms of non small cell lung cancer: BDTX-1535 and BDTX-4933. #NSCLC #EGFR #KRAS

To read more about Lung Cancer Awareness Month, visit American Lung Association: https://lnkd.in/dnXYGtR

And to learn more about Black Diamond’s unique approach to targeting families of oncogenic mutations, click here: https://lnkd.in/em4gMAWM

	Dec '17	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
account payables	152K -	416K 173.68%	1.96M 372.12%	2.54M 29.23%	4.11M 61.82%	1.88M 54.30%	2.32M 23.81%
accumulated other comprehensive income loss	-56K -	-100K 78.57%	-1K 99%	614K 61,500%	-414K 167.43%	-1.82M 340.58%	-27K 98.52%
cash and cash equivalents	7.88M -	51.66M 555.75%	154.67M 199.39%	34.60M 77.63%	65.80M 90.14%	34.31M 47.85%	56.22M 63.84%
cash and short term investments	7.88M -	51.66M 555.75%	154.67M 199.39%	315.07M 103.71%	209.79M 33.42%	122.81M 41.46%	131.40M 7.00%
common stock	1K -	1K 0%	1K 0%	5K 400%	5K 0%	5K 0%	7K 40%
deferred revenue
deferred revenue non current
deferrred tax liabilities non current
goodwill
goodwill and intangible assets
intangible assets
inventory
long term debt				7.69M -	28.14M 265.74%	25.30M 10.10%	22.18M 12.31%
long term investments							823K -
net debt	-7.88M -	-51.66M 555.75%	-154.67M 199.39%	-25.86M 83.28%	-37.34M 44.37%	-6.17M 83.46%	-30.92M 400.78%
net receivables
other assets							1 -
other current assets	36K -	24K 33.33%	1.05M 4,266.67%	4.49M 328.15%	5.92M 31.87%	4.90M 17.20%	2.63M 46.23%
other current liabilities	2.08M -	2.16M 3.90%	2.90M 34.28%	10.63M 266.78%	19.21M 80.71%	10.54M 45.13%	14.21M 34.77%
other liabilities			3.81M -		439.72M -
other non current assets	5K -	8K 60%	3.46M 43,212.50%	1.33M 61.65%	7.16M 438.45%	1.17M 83.68%
other non current liabilities	12.47M -	64.79M 419.76%	200.59M 209.58%
othertotal stockholders equity	-12.30M -	-60.50M 392.00%	-200.57M 231.52%	-330.29M 64.67%	409K 100.12%	1.82M 344.74%	534.19M 29,267.07%
preferred stock	12.46M -	60.77M 387.80%	200.57M 230.05%	329.67M 64.36%
property plant equipment net	102K -	134K 31.37%	164K 22.39%	8.79M 5,257.93%	30.74M 249.83%	27.38M 10.93%	23.71M 13.41%
retained earnings	-6.78M -	-15.71M 131.71%	-50.97M 224.40%	-118.22M 131.95%	-243.82M 106.24%	-334.99M 37.39%	-417.43M 24.61%
short term debt				1.05M -	320K 69.44%	2.84M 787.81%	3.11M 9.57%
short term investments				280.46M -	143.99M 48.66%	88.49M 38.54%	75.18M 15.04%
tax assets
tax payables
total assets	8.02M -	51.83M 546.13%	158.29M 205.44%	329.67M 108.26%	247.68M 24.87%	156.25M 36.91%	158.57M 1.48%
total current assets	7.91M -	51.68M 553.07%	154.67M 199.25%	319.55M 106.61%	209.79M 34.35%	127.71M 39.13%	134.03M 4.96%
total current liabilities	2.23M -	2.58M 15.47%	4.86M 88.85%	14.22M 192.37%	23.64M 66.28%	15.26M 35.45%	19.65M 28.73%
total debt				8.74M -	28.46M 225.59%	28.14M 1.12%	25.30M 10.10%
total investments				280.46M -	143.99M 48.66%	88.49M 38.54%	76.00M 14.11%
total liabilities	14.70M -	67.37M 358.41%	209.26M 210.63%	21.91M 89.53%	491.50M 2,143.07%	40.56M 91.75%	41.83M 3.13%
total liabilities and stockholders equity	8.02M -	51.83M 546.13%	158.29M 205.44%	-96.31M 160.84%	247.68M 357.17%	-294.43M 218.87%	158.57M 153.86%
total non current assets	107K -	142K 32.71%	3.63M 2,455.63%	10.12M 178.75%	37.90M 274.61%	28.55M 24.66%	24.53M 14.07%
total non current liabilities	12.47M -	64.79M 419.76%	200.59M 209.58%	7.69M 96.16%	28.14M 265.74%	25.30M 10.10%	22.18M 12.31%
total stockholders equity	-6.67M -	-15.54M 132.84%	-50.97M 227.95%	-118.22M 131.95%	-243.82M 106.24%	-334.99M 37.39%	116.74M 134.85%

COM:BLACKDIAMONDTHERAPEUTICS

Black Diamond Therapeutics

Last Close

2.43

22/11 21:00

Market Cap

288.58M

Beta: -

Volume Today

338

Avg: -

Preview